Literature DB >> 9652666

Spectrum of AIDS-associated malignant disorders.

J J Goedert1, T R Coté, P Virgo, S M Scoppa, D W Kingma, M H Gail, E S Jaffe, R J Biggar.   

Abstract

BACKGROUND: To clarify which types of cancer result from AIDS, we compared the cancer experiences of people with AIDS with those of the general population by matching population-based cancer and AIDS registries in the USA and Puerto Rico.
METHODS: We used a probabilistic matching algorithm to compare names, birth dates, and, where available, social-security numbers of 98,336 people with AIDS and 1,125,098 people with cancer aged less than 70 years. We defined AIDS-related cancers as those with both significantly raised incidence post-AIDS and increasing prevalence from 5 years pre-AIDS to 2 years post-AIDS.
FINDINGS: Among people with AIDS, we found 7028 cases of Kaposi's sarcoma (KS), 1793 of non-Hodgkin lymphoma (NHL), and 712 other cases of histologically defined cancer. Incidence rates among people with AIDS were increased 310-fold for KS, 113-fold for NHL, and 1.9-fold (95% CI 1.5-2.3) for other cancers. Of 38 malignant disorders other than KS and NHL, only angiosarcoma (36.7-fold), Hodgkin's disease (7.6-fold), multiple myeloma (4.5-fold), brain cancer (3.5-fold), and seminoma (2.9-fold) were raised and increasing significantly (p<0.02) from the pre-AIDS to the post-AIDS period.
INTERPRETATION: Interpretation is complicated by screening and shared risk factors, such as sexual behaviour and cigarette smoking. However, our data indicate that AIDS leads to a significantly increased risk of Hodgkin's disease, multiple myeloma, brain cancer, and seminoma. Immunological failure to control herpes or other viral infections may contribute to these malignant diseases.

Entities:  

Mesh:

Year:  1998        PMID: 9652666     DOI: 10.1016/s0140-6736(97)09028-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  157 in total

1.  Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Swiss HIV Cohort Study.

Authors:  B Ledergerber; A Telenti; M Egger
Journal:  BMJ       Date:  1999-07-03

2.  Socioeconomic status and multiple myeloma among US blacks and whites.

Authors:  D Baris; L M Brown; D T Silverman; R Hayes; R N Hoover; G M Swanson; M Dosemeci; A G Schwartz; J M Liff; J B Schoenberg; L M Pottern; J Lubin; R S Greenberg; J F Fraumeni
Journal:  Am J Public Health       Date:  2000-08       Impact factor: 9.308

Review 3.  Non-lymphomatous brain tumors in HIV-1 infection: a review.

Authors:  A Büttner; S Weis
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

4.  Opportunistic intestinal infections and risk of colorectal cancer among people with AIDS.

Authors:  Fatma M Shebl; Eric A Engels; James J Goedert
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02-02       Impact factor: 2.205

5.  Cancer in cohort of HIV-infected population: prevalence and clinical characteristics.

Authors:  Yong-xi Zhang; Xi-en Gui; Ya-hua Zhong; Yu-ping Rong; Ya-jun Yan
Journal:  J Cancer Res Clin Oncol       Date:  2010-06-08       Impact factor: 4.553

Review 6.  Clinical epidemiology of testicular germ cell tumors.

Authors:  K-P Dieckmann; U Pichlmeier
Journal:  World J Urol       Date:  2004-03-18       Impact factor: 4.226

7.  Cancer Treatment in Patients With HIV Infection and Non-AIDS-Defining Cancers: A Survey of US Oncologists.

Authors:  Gita Suneja; Matthew Boyer; Baligh R Yehia; Meredith S Shiels; Eric A Engels; Justin E Bekelman; Judith A Long
Journal:  J Oncol Pract       Date:  2015-04-14       Impact factor: 3.840

8.  Cancer incidence in a Nationwide HIV/AIDS patient cohort in Taiwan in 1998-2009.

Authors:  Marcelo Chen; Ian Jen; Yi-Hsien Chen; Ming-Wei Lin; Kishor Bhatia; Gerald B Sharp; Matthew G Law; Yi-Ming Arthur Chen
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

9.  Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Authors:  Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

10.  Aetiology of colorectal cancer and relevance of monogenic inheritance.

Authors:  M Ponz de Leon; P Benatti; F Borghi; M Pedroni; A Scarselli; C Di Gregorio; L Losi; A Viel; M Genuardi; G Abbati; G Rossi; M Menigatti; I Lamberti; G Ponti; L Roncucci
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.